恒瑞医药SHR-1139注射液临床试验获批

Core Viewpoint - Heng Rui Medicine's subsidiary, Guangdong Heng Rui Medicine Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-1139 injection, aimed at treating necrotizing pyoderma, marking a significant step in the company's drug development efforts [1] Group 1 - SHR-1139 injection is a biopharmaceutical independently developed by Heng Rui Medicine [1] - There are currently no similar drugs approved for market in both domestic and international markets [1]